Ocular Therapeutix Stock Alpha and Beta Analysis
| OCUL Stock | USD 8.83 0.31 3.64% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Ocular Therapeutix. It also helps investors analyze the systematic and unsystematic risks associated with investing in Ocular Therapeutix over a specified time horizon. Remember, high Ocular Therapeutix's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Ocular Therapeutix's market risk premium analysis include:
Beta 1.84 | Alpha (0.26) | Risk 3.44 | Sharpe Ratio 0.0076 | Expected Return 0.026 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Ocular |
Ocular Therapeutix Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Ocular Therapeutix market risk premium is the additional return an investor will receive from holding Ocular Therapeutix long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Ocular Therapeutix. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Ocular Therapeutix's performance over market.| α | -0.26 | β | 1.83 |
Ocular Therapeutix expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Ocular Therapeutix's Buy-and-hold return. Our buy-and-hold chart shows how Ocular Therapeutix performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Ocular Therapeutix Market Price Analysis
Market price analysis indicators help investors to evaluate how Ocular Therapeutix stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Ocular Therapeutix shares will generate the highest return on investment. By understating and applying Ocular Therapeutix stock market price indicators, traders can identify Ocular Therapeutix position entry and exit signals to maximize returns.
Ocular Therapeutix Return and Market Media
The median price of Ocular Therapeutix for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 9.22 with a coefficient of variation of 10.68. The daily time series for the period is distributed with a sample standard deviation of 1.03, arithmetic mean of 9.61, and mean deviation of 0.92. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Donald Notman of 33602 shares of Ocular Therapeutix at 8.56 subject to Rule 16b-3 | 08/29/2024 |
2 | Acquisition by Summer Road Llc of 930851 shares of Ocular Therapeutix at 7.52 subject to Rule 16b-3 | 09/06/2024 |
3 | Shareholders have faith in loss-making Ocular Therapeutix as stock climbs 3.8 percent in past week, taking one-year gain to 177 | 09/20/2024 |
4 | Insider Trading | 10/02/2024 |
5 | Acquisition by Heier Jeffrey S. of 100000 shares of Ocular Therapeutix subject to Rule 16b-3 | 10/04/2024 |
6 | Ocular Therapeutix Moves 6.1 percent Higher Will This Strength Last | 10/14/2024 |
7 | Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI in Wet AMD | 10/15/2024 |
8 | Ocular Therapeutix Given Buy Rating at HC Wainwright | 10/17/2024 |
9 | Vanguard Group Incs Strategic Reduction in Ocular Therapeutix Inc Holdings | 11/05/2024 |
10 | OmniAb, Inc. Reports Q3 Loss, Lags Revenue Estimates | 11/12/2024 |
11 | What To Expect From Ocular Therapeutix Inc Q3 2024 Earnings | 11/13/2024 |
12 | Ocular Therapeutix Inc earnings beat by 0.02, revenue fell short of estimates | 11/14/2024 |
13 | Ocular Therapeutix Inc Q3 2024 Earnings Call Highlights Strong Financial Position and ... | 11/15/2024 |
14 | Ocular Therapeutix Given New 15.00 Price Target at HC Wainwright | 11/18/2024 |
About Ocular Therapeutix Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Ocular or other stocks. Alpha measures the amount that position in Ocular Therapeutix has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.96 | 0.89 | 1.2 | 2.26 | Days Of Inventory On Hand | 103.55 | 158.7 | 159.31 | 201.23 |
Ocular Therapeutix Upcoming Company Events
As portrayed in its financial statements, the presentation of Ocular Therapeutix's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ocular Therapeutix's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Ocular Therapeutix's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Ocular Therapeutix. Please utilize our Beneish M Score to check the likelihood of Ocular Therapeutix's management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Ocular Therapeutix
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Ocular Therapeutix Backtesting, Ocular Therapeutix Valuation, Ocular Therapeutix Correlation, Ocular Therapeutix Hype Analysis, Ocular Therapeutix Volatility, Ocular Therapeutix History and analyze Ocular Therapeutix Performance. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Ocular Therapeutix technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.